Abstract
Twenty-three patients with malignant melanoma metastatic to the central nervous system (CNS) were treated with intracarotid cisplatin-based chemotherapy. Twenty-two had failed prior cranial radiation therapy (one patient refused radiation therapy) and had progressive brain metastases documented by computerized tomography (CT). Intracarotid cisplatin 40-75 mg/m2 was administered alone (seven patients) with 1,3-bis(2-Chloroethyl)-1-nitrosurea (BCNU) (13 patients) or bleomycin (three patients). Courses were repeated monthly with CT scan. Seven patients (30%) had objective improvement in CT scans and three patients (13%) had stabilization of disease. The median time to tumor progression for responding patients was 20 weeks (range 8-34 weeks) while stable disease ranged from 9-12 weeks. In three patients the extracranial disease progressed while the brain metastases responded. Neurological and retinal toxicity were potential complications of therapy. Intracarotid cisplatin-based chemotherapy may be useful for palliation in selected patients with malignant melanoma and CNS metastases.
| Original language | English |
|---|---|
| Pages (from-to) | 448-451 |
| Number of pages | 4 |
| Journal | American Journal of Clinical Oncology: Cancer Clinical Trials |
| Volume | 13 |
| Issue number | 5 |
| State | Published - Jan 1 1990 |
Fingerprint
ASJC Scopus subject areas
- Cancer Research
- Oncology
Cite this
Intracarotid cisplatin-based chemotherapy in patients with malignant melanoma and central nervous system (CNS) metastases. / Feun, Lynn G; Lee, Y. Y.; Plager, C.; Papadopoulos, N.; Savaraj, Niramol; Charnsangavej, C.; Benjamin, R. S.; Wallace, S.
In: American Journal of Clinical Oncology: Cancer Clinical Trials, Vol. 13, No. 5, 01.01.1990, p. 448-451.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Intracarotid cisplatin-based chemotherapy in patients with malignant melanoma and central nervous system (CNS) metastases
AU - Feun, Lynn G
AU - Lee, Y. Y.
AU - Plager, C.
AU - Papadopoulos, N.
AU - Savaraj, Niramol
AU - Charnsangavej, C.
AU - Benjamin, R. S.
AU - Wallace, S.
PY - 1990/1/1
Y1 - 1990/1/1
N2 - Twenty-three patients with malignant melanoma metastatic to the central nervous system (CNS) were treated with intracarotid cisplatin-based chemotherapy. Twenty-two had failed prior cranial radiation therapy (one patient refused radiation therapy) and had progressive brain metastases documented by computerized tomography (CT). Intracarotid cisplatin 40-75 mg/m2 was administered alone (seven patients) with 1,3-bis(2-Chloroethyl)-1-nitrosurea (BCNU) (13 patients) or bleomycin (three patients). Courses were repeated monthly with CT scan. Seven patients (30%) had objective improvement in CT scans and three patients (13%) had stabilization of disease. The median time to tumor progression for responding patients was 20 weeks (range 8-34 weeks) while stable disease ranged from 9-12 weeks. In three patients the extracranial disease progressed while the brain metastases responded. Neurological and retinal toxicity were potential complications of therapy. Intracarotid cisplatin-based chemotherapy may be useful for palliation in selected patients with malignant melanoma and CNS metastases.
AB - Twenty-three patients with malignant melanoma metastatic to the central nervous system (CNS) were treated with intracarotid cisplatin-based chemotherapy. Twenty-two had failed prior cranial radiation therapy (one patient refused radiation therapy) and had progressive brain metastases documented by computerized tomography (CT). Intracarotid cisplatin 40-75 mg/m2 was administered alone (seven patients) with 1,3-bis(2-Chloroethyl)-1-nitrosurea (BCNU) (13 patients) or bleomycin (three patients). Courses were repeated monthly with CT scan. Seven patients (30%) had objective improvement in CT scans and three patients (13%) had stabilization of disease. The median time to tumor progression for responding patients was 20 weeks (range 8-34 weeks) while stable disease ranged from 9-12 weeks. In three patients the extracranial disease progressed while the brain metastases responded. Neurological and retinal toxicity were potential complications of therapy. Intracarotid cisplatin-based chemotherapy may be useful for palliation in selected patients with malignant melanoma and CNS metastases.
UR - http://www.scopus.com/inward/record.url?scp=0025091706&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0025091706&partnerID=8YFLogxK
M3 - Article
C2 - 1699402
AN - SCOPUS:0025091706
VL - 13
SP - 448
EP - 451
JO - American Journal of Clinical Oncology
JF - American Journal of Clinical Oncology
SN - 0277-3732
IS - 5
ER -